Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Biotechnology

Healthcare
$247.77 +0.02%

+$0.05 today

Market cap
$15.90B
Beta
0.33
P/E (TTM)
476.3
EPS (TTM)
$0.48
52W Low $105.00High $243.32

Volume 0.72M

Average 0.92M

JAZZ Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Jazz Pharmaceuticals plcNASDAQ: JAZZ

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin narrows to 0.0%

Gross margin was 0.0% in Q3 FY2026, down 77.1 pp from a year earlier. On a trailing-twelve-month basis it was 64.2%, down 21.2 pp year over year. Over 3 fiscal years it widened by 3.0 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
0.0%-90.4 pp QoQ
Last fiscal yearDec 2025
88.2%-0.8 pp YoY
LTMSep 2026
64.2%-21.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-77.1 pp——
1 year-0.8 pp——
3 years+3.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
88.2%
Year-over-year change
-0.8pp

Gross Margin vs competitors

How JAZZ compares with its peers on the latest reported figures

  • JAZZ's LTM Sep 2026 gross margin of 64.2% is the 8th highest of the 9 companies compared; the peer median is 87.7%.
  • Its year-over-year change of -21.2 pp is the lowest of 8, against a peer median of -0.6 pp.
  • Over three fiscal years its change of +3.0 pp compares with a peer median of -2.5 pp.
JAZZ Competitors Peer median
Gross Margin for JAZZ and competitors
Company Period LTM level YoY 3-year change
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202698.6% +10.9 pp+24.5 pp
NBIXNeurocrine Biosciences, Inc.LTM Sep 202697.8% -0.6 pp-0.3 pp
GMABGenmab A/SLTM Jun 202693.0% —-8.3 pp
INCYIncyte CorporationLTM Jun 202692.6% -0.3 pp-1.1 pp
TGTXTG Therapeutics, Inc.LTM Sep 202682.7% -2.6 pp-6.8 pp
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 202675.4% -2.9 pp-3.8 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
JAZZJazz Pharmaceuticals plcLTM Sep 202664.2% -21.2 pp+3.0 pp
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
Peer median (excluding JAZZ) 87.7%-0.6 pp-2.5 pp

Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.09B3.66B3.83B4.07B4.27B
Cost of Revenue440.76M540.52M435.58M445.71M503.3M
Gross Profit2.65B3.12B3.4B3.62B3.76B
Gross Margin85.8%85.2%88.6%89.0%88.2%
Research & Development505.75M590.45M849.66M884M782.74M
Selling, General & Admin1.45B1.42B1.34B1.39B1.81B
Operating Expenses2.48B3.18B2.82B2.91B3.54B
Depreciation & Amortization552.48M629.47M638.7M660.07M696.3M
EBITDA1.03B1.47B1.45B1.52B262.76M
EBITDA Margin33.2%40.1%37.8%37.4%6.2%
Operating Income170.28M(65.53M)578.58M716.63M224.42M
Operating Margin5.5%-1.8%15.1%17.6%5.3%
Interest Income00000
Interest Expense278.77M288.24M289.44M238.1M195.05M
Other Income / Expenses(283.83M)(317.18M)(283.66M)(247.94M)(853.01M)
Income Before Tax(113.55M)(382.71M)294.92M468.69M(628.59M)
Pre-Tax Margin-3.7%-10.5%7.7%11.5%-14.7%
Income Tax Expense216.12M(158.65M)(119.91M)(91.43M)(272.44M)
Net Income(328.95M)(224.06M)414.83M560.12M(356.15M)
Net Margin-10.6%-6.1%10.8%13.8%-8.3%
EPS (Basic)(5.51)(3.58)6.559.06(5.84)
EPS (Diluted)(5.51)(3.58)6.108.65(5.84)
Weighted Avg Shares59.69M62.54M63.29M61.84M60.98M
Weighted Avg Shares (Diluted)59.69M62.54M72.07M66.01M60.98M

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Intrinsic Alpha fair value

Locked

Current Price

$247.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.